400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / Cell Cycle / PLK / TAK-960
CAS No.: 1137868-52-0
Synonyms: TAK-960
TAK-960 is an investigational, orally bioavailable, potent, and selective PLK1 inhibitor (IC50=1.5 nM) that has shown activity in several tumor cell lines, including those that express multidrug-resistant protein 1 (MDR1).
生物活性
靶点 | PLK1 IC50:1.5nM |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT01179399 | Advanced Nonhematological Mali... more >>gnancies Collapse << | Phase 1 | Terminated | - | United States, Texas ... more >> South Texas Accelerated Research Therapeutics (START) San Antonio, Texas, United States, 78229 United States, Utah Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 Collapse << |
NCT01179399 | - | - | Terminated | - | - |
实验方案
技术信息
CAS号 | 1137868-52-0 | 储存条件 |
|
|||
分子式 | C27H34F3N7O3 | 运输 | 蓝冰 | |||
分子量 | 561.60 | 别名 | TAK-960 | |||
溶解度 |
|
动物实验配方 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT01179399 | Advanced Nonhematological Mali... more >>gnancies Collapse << | Phase 1 | Terminated | - | United States, Texas ... more >> South Texas Accelerated Research Therapeutics (START) San Antonio, Texas, United States, 78229 United States, Utah Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 Collapse << |
NCT01179399 | - | - | Terminated | - | - |
靶点 | Description | IC50 |
---|---|---|
PLK1 | IC50:1.5nM |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网